Bayer to buy remaining stake in BlueRock Therapeutics

This article was originally published here

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),

The post Bayer to buy remaining stake in BlueRock Therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply